Status:
COMPLETED
MEXIDOL® in the Rehabilitation Treatment of Patients With Acute Cerebral Failure
Lead Sponsor:
Pharmasoft
Conditions:
Ischemic Stroke, Acute
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The use of metabolic modulators creates prospects for increasing the efficiency of the rehabilitation treatment of patients with acute cerebral failure
Detailed Description
Modern neurorehabilitation is a set of basic and adjuvant treatment methods that provide a modulating effect on the neurorestoration process. The range of basic rehabilitation practices includes kines...
Eligibility Criteria
Inclusion
- Acute Ischemic Stroke
- Montreal Cognitive Assessment (MoCA) test \>15; ≤22
Exclusion
- Under 18 years old
- Epilepsy
- Pregnancy
- Acute failure of one or more organ systems
- Purulent-inflammatory disease of any localization
- Participating in any other clinical trial
Key Trial Info
Start Date :
April 17 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 12 2023
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06221826
Start Date
April 17 2023
End Date
September 12 2023
Last Update
April 27 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Brain Institute Clinic
Yekaterinburg, Sverdlovsk Oblast, Russia, 623702